Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) registered a 4.94% increase, still its new closing price is 34.72% up from the company’s 1 year high of 65.64.It posted 3.86% gains in previous 5 sessions and is now the subject of 5 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 3 buy or better ratings. The 13 stock analysts following this company have an average price target at $50.33, with individual PT in the $34.00-$89.00 range. The shares moved at $40.35, implying that brokerage firms see shares losing about -34.37% in twelve months time.
Pacira Pharmaceuticals, Inc. (PCRX) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a 24.92% rise year to date. A President at Pacira Pharmaceuticals, Inc. (PCRX) offloaded shares in a transaction closed on Tuesday January 17, 2017. Scibetta James S sold 20,000 shares in the company at $38.53 each and collected $770,001 in proceeds. Scibetta James S now owns 27,084 shares in the company after this transaction. A CEO and Chairman in the company, STACK DAVID M, disclosed a transaction on Tuesday January 17, 2017 that ended up generating $576,000 from the sale of 15,000 shares at $38.41 per share.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Upcoming Results on Tap
Pacira Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $0.19 in that period. Sales during the quarter are predicted to arrive at $72.14 million.
Earnings surprise history: Last quarter, the company posted approximately $63.35 million in revenue and EPS of $0.20. The mean forecast was for $67.16 million and $-0.02 a share, respectively. One quarter earlier, revenue for the stock was at $69.64 million, with earnings at $0.19/share.
Pacira Pharmaceuticals, Inc. (PCRX) Brokerage Update
Pacira Pharmaceuticals, Inc. (PCRX) is in Brean Capital’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by Brean Capital, according to news reported on Friday July 01, 2016.Another important research note was issued by BofA/Merrill on Friday January 29, 2016.The firm upgraded PCRX to Buy from Neutral. Over the last six months and over the last three months, the shares of Pacira Pharmaceuticals, Inc. (PCRX), have changed 5.96% and 26.89%, respectively.